These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20085126)

  • 1. The need for individualised antipsychotic drug therapy in patients with schizophrenia.
    Pani L
    Eur Rev Med Pharmacol Sci; 2009; 13(6):453-9. PubMed ID: 20085126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drugs for schizophrenia: an update for family physicians.
    Amadio PB; Cross LB; Amadio P
    Am Fam Physician; 1997 Sep; 56(4):1149-56, 1159-60. PubMed ID: 9310066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology, etiology, diagnosis, and treatment of schizophrenia.
    Ryan PM
    Am J Hosp Pharm; 1991 Jun; 48(6):1271-80. PubMed ID: 1677528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
    Faludi G
    Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meeting everyday challenges: antipsychotic therapy in the real world.
    Gorwood P
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S156-62. PubMed ID: 16872807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
    Gerlach J
    J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a cross-sectional national survey.
    Diatta T; Blazejewski S; Portier A; Lignot S; Quesnot A; Moore N; Fourrier-Réglat A
    Fundam Clin Pharmacol; 2007 Aug; 21(4):371-8. PubMed ID: 17635175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight change with atypical antipsychotics in the treatment of schizophrenia.
    Haddad P
    J Psychopharmacol; 2005 Nov; 19(6 Suppl):16-27. PubMed ID: 16280334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial response to antipsychotic treatment: the patient with enduring symptoms.
    Emsley RA
    J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of atypical antipsychotic drugs.
    Grundmann M; Kacirova I; Urinovska R
    Acta Pharm; 2014 Dec; 64(4):387-401. PubMed ID: 25531781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing and measuring nonresponse in schizophrenia.
    Kane JM
    J Clin Psychiatry; 2012 Jan; 73(1):e04. PubMed ID: 22316583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.